Pluristem Therapeutics has received approval from the Paul-Ehrlich-Institute, Germany's health authority, to provide cells from its advanced, fully automated, and proprietary 3D cell expansion manufacturing platform implemented at its new GMP facility. The company's new manufacturing facility has the capability to efficiently produce more than 150,000 doses of PLX cells per annum. This step represents the first regulatory approval of the company's new facility, where the company has implemented its large scale 3D bioreactor expansion of placental-derived mesenchymal-like Adherent Stromal Cells.